JNJ beat on profit and revenue yet shares fell about 4%: pharma grew on Tremfya while Stelara declined, and medical technology rose only 2.5% to $8.6B, below expectations — blamed on the Middle East conflict, European austerity and China price pressure, the source of the stock's weakness.

Let's talk about Johnson & Johnson. At Johnson & Johnson, the picture is weaker , with shares under pressure and down about 4% despite the company beating expectations in net profit.

Earnings amounted to $2.59 per share . Analysts had expected $2.53 per share. Revenues also recorded a slight increase, reaching $25.4 billion. The market had been expecting $25.25 billion for Johnson & Johnson, but they noted there would be some impact on the medical technology sector .

That was the weakest point, and some of that is due to the geopolitical conflict they mentioned. Sales outside the United States were essentially stable . Once again, total revenues reached $25.4 billion, while the expected amount was $25.25 billion.

The pharmaceutical sector is what has fueled growth here. The drugs, specifically Tremvia, were pioneers in this field . Sales of that property jumped by 68%. As for the Stellara drug, it has seen a decline.

There was competition in this area, but they are looking for other ways to compensate for that. Therefore, part of that decline has been offset in Stellara, but medical technology remains the weak point here.

Sales of medical technology increased, but only by 2.5% to reach $8.6 billion. Therefore, this was less than expected. The company referred to the conflict in the Middle East .

They stated this to Reuters. In addition to European austerity measures and price pressures in China. So , the larger global picture is causing some weakness in medical technology sales, and that's why the stock has been hurt.

Yes, it is down by about 4% at the moment.